Shares of Haemonetics Corporation (NYSE: HAE) surged 8.75% in pre-market trading on Thursday following the release of its second quarter fiscal 2026 financial results. The medical technology company specializing in blood and plasma supplies and services reported earnings that significantly surpassed analyst expectations.

Haemonetics posted quarterly revenue of $327.3 million, beating the FactSet consensus estimate of $311.5 million. This represents a 5% decrease compared to the same period last year, primarily due to the impact of its CSL Plasma business. However, excluding CSL, the company's organic revenue increased by an impressive 9.4% for the quarter.

The company's adjusted earnings per share (EPS) came in at $1.27, substantially higher than the FactSet estimate of $0.99. This marks a 13.39% increase from the $1.12 per share reported in the same quarter last year. Furthermore, Haemonetics raised its total company fiscal 2026 guidance, signaling confidence in its future performance. The strong results and positive outlook appear to be driving investor enthusiasm, as reflected in the significant pre-market stock movement.